Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemarituzumab - Amgen

Drug Profile

Bemarituzumab - Amgen

Alternative Names: AMG-552; Anti-FGFR2b antibody - Five Prime Therapeutics; FPA-144

Latest Information Update: 13 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galaxy Biotech
  • Developer Amgen; Five Prime Therapeutics; ZAI Lab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 08 Feb 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Argentina, Brazil, Finland, Italy, Romania (IV) (NCT05325866)
  • 08 Feb 2024 Phase-III clinical trials in Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Switzerland, Hong Kong, Czech Republic, Chile, Bulgaria, Austria, Romania (IV) (NCT05111626)
  • 08 Feb 2024 Phase-III clinical trials in Oesophageal cancer (Combination therapy, Inoperable/Unresectable, First-line therapy, Late-stage disease, Metastatic disease) in Austria, Bulgaria, Czech Republic, Chile, Hong Kong, Romania, Switzerland (IV) (NCT05111626)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top